NASDAQ OMX

Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

Dela

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2018.

"Minerva now has five late-stage clinical efficacy trials ongoing with three compounds," said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.  "These include our lead product, roluperidone (MIN-101) for schizophrenia, MIN-117 for MDD and seltorexant (MIN-202) for insomnia disorder and MDD. 

"In schizophrenia, the leading unmet medical need as ranked by psychiatrists is negative symptoms, the target indication for roluperidone," said Dr. Luthringer.  "Based on the improvement in negative symptoms measured in clinical tests with roluperidone to date, combined with the observed stability in positive symptoms and a favorable side effect profile, we believe this compound has the potential to be a differentiated therapy in schizophrenia, and we are working on commercialization strategies that address this significant commercial opportunity."

Clinical Development Updates

Roluperidone (MIN-101):

  • The Company's clinical sites in the U.S. are actively enrolling patients in the pivotal Phase 3 trial with roluperidone.  The Company has prioritized the initiation of U.S. sites, and now European sites have been initiated. Target enrollment in this trial is approximately 500 patients.  Top-line results are expected in the first half of 2019.

MIN-117:

  • As announced on April 9, 2018, the Company has enrolled the first patient in a Phase 2b trial of MIN-117 to treat the symptoms of patients diagnosed with MDD.  Approximately 324 patients will be enrolled at clinical sites in the U.S. and Europe. Top-line results are expected in the first half of 2019.

Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • Three Phase 2b clinical trials are ongoing with seltorexant, including two in MDD and one in insomnia disorder.  In the first MDD trial, approximately 280 patients are planned to be enrolled at clinical sites in the U.S., Europe and Japan.  In the second MDD trial, approximately 100 patients are planned to be randomized at clinical sites in the U.S.  The insomnia trial is expected to enroll a total of approximately 360 patients at clinical sites in the U.S., Europe and Japan. These trials are planned for completion in 2019.

First Quarter 2018 Financial Results

  • Net Loss:  Net loss was $12.4 million for the first quarter of 2018, or a loss per share of $0.32 (basic and diluted), compared to a net loss of $10.6 million for the first quarter of 2017, or a loss per share of $0.30 (basic and diluted).
     
  • R&D Expenses: Research and development (R&D) expenses were $8.4 million in the first quarter of 2018, compared to $7.6 million in the first quarter of 2017.  The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. These amounts were partially offset by lower development expenses for the seltorexant program due to the amendment to the Company's Co-Development and License Agreement with Janssen.  R&D expenses are expected to increase during 2018 with increased patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
     
  • G&A Expenses: General and administrative (G&A) expenses were $4.3 million in the first quarter of 2018, compared to $2.9 million in the first quarter of 2017. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support the Company's pre-commerical activities.  G&A expenses are expected to increase during 2018 with investment in the infrastructure necessary to support the Company's growth.
     
  • Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2018 were approximately $121.1 million. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 8885379.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

   
CONDENSED CONSOLIDATED BALANCE SHEET DATA  
(Unaudited)  
  March 31, December 31,  
  2018     2017    
  (in thousands)  
ASSETS  
Current Assets:      
Cash and cash equivalents $   45,126   $   26,052    
Marketable securities     75,871       102,109    
Restricted cash     100       80    
Prepaid expenses and other current assets     4,243       1,299    
Total current assets     125,340       129,540    
Marketable securities - noncurrent     -        5,023    
Equipment, net     47       51    
Other noncurrent assets     15       15    
In-process research and development     34,200       34,200    
Goodwill     14,869       14,869    
Total Assets $   174,471   $   183,698    
       
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current Liabilities:      
Notes payable $   2,697   $   3,962    
Accounts payable     2,825       1,436    
Accrued expenses and other current liabilities     2,393       1,439    
Total current liabilities     7,915       6,837    
Long-Term Liabilities:      
Deferred taxes     4,057       4,057    
Deferred revenue     41,176       41,176    
Other noncurrent liabilities     30       30    
Total liabilities     53,178       52,100    
Stockholders' Equity:      
Common stock     4       4    
Additional paid-in capital     298,089       295,975    
Accumulated deficit     (176,800 )     (164,381 )  
Total stockholders' equity     121,293       131,598    
Total Liabilities and Stockholders' Equity $   174,471   $   183,698    
       

 

 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)      
    Three Months Ended March 31,
    (in thousands, except per share amounts)
      2018     2017  
       
Revenues   $   -    $   -   
Operating expenses:      
Research and development       8,449       7,614  
General and administrative       4,294       2,871  
Total operating expenses       12,743       10,485  
       
Foreign exchange losses       (18 )     (17 )
Investment income       414       59  
Interest expense       (71 )     (202 )
Net income (loss)   $   (12,418 ) $   (10,645 )
Loss per share:      
Basic and diluted   $   (0.32 ) $   (0.30 )
Weighted average shares:      
Basic and diluted       38,749       35,370  
       

 

Contact :

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressmeddelande

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

BIMobject AB: BIMobject publicerar årsredovisning för 201718.5.2018 17:25Pressmeddelande

BIMobject, som digitaliserar byggbranschen bland annat via molnbaserade plattformar, har idag publicerat årsredovisningen för 2017 på bolagets hemsida. "Det är med stolthet vi offentliggör årsredovisningen för året 2017 - ett år som för oss inte kan beskrivas annat än som 'explosivt'. Det är fantastiskt roligt att se hur vi fortsätter att effektivisera branscher som äntligen börjar se nyttan och digitaliseringens fulla potential. Att vi sedan har fyra starka trender som ger oss vind i seglet gör framtiden ännu mer lockande. Nu är vi i ett spännande 2018 där vi bland annat ser fram emot att passera milstolpen 1 miljon användare", säger Stefan Larsson, VD på BIMobject. Årsredovisningen finns tillgänglig för nedladdning på: http://info.bimobject.com/bimobject_data/documents/Documents/2017/bimobject-%C3%A5rsredovisning-2017.pdf För mer information, vänligen kontakta: Stefan Hansson - CFO Tel: +46 40 - 685 29 00 E-mail: press@bimobject.com ______________________________________________ Denn

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressmeddelande

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

Mandalay Resources Corporation går ut med resultaten från årsstämman samt registreringen av ESTMA-rapporten och utnämningen av styrelseledamot17.5.2018 22:00Pressmeddelande

TORONTO den 17 maj 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) har nöjet att meddela resultatet från årsstämman ("årsstämman") som hölls i dag i Toronto, Ontario. Alla resolutioner som presenterades vid årsstämman godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 79,15 % av de totalt utestående aktierna vid tidsfristen för fullmakter den 14 maj 2018. Val av styrelseledamöter Som meddelat den 14 maj 2018, har Mark Sander avgått som Bolagets President och Chief Executive Officer och drog också tillbaka sin kandidatur för återval till styrelsen. Som resultat fastställdes antalet styrelseledamöter till fem medlemmar och samtliga av de fem nominerade som fanns i bolagsledningens informationsutskick från den 13 april 2018 ("informationsutskicket"), undantaget Mark Sander, valdes om till Bolagets styrelse. Abraham Jonker förblir ledande oberoende styrelseledamot och Bradford Mills fortsätter som styrelseordförande.

Skybox Security and Exclusive Networks Announce New Partnership for Middle East Distribution of the Skybox Security Suite17.5.2018 18:41Pressmeddelande

The cybersecurity management platform ensures networks remain secure and compliant as organisations migrate to cloud and merge networks SAN JOSE, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today a new partnership with Exclusive Networks for distribution of Skybox solutions in the Middle East, including the Gulf Cooperation Council (GCC) region and Egypt. Exclusive Networks will deploy and service the Skybox(TM) Security Suite, a broad security management platform that provides comprehensive attack surface visibility and enables unified vulnerability management and firewall/security policy management across an organization's entire network, including in physical, multi-cloud and OT environments. "Driven by government outlays (with oil, gas and defence industries leading the charge), Middle East organisations are looking for trusted security advisors who can navigate digital transformations and reduce risks - espec

Dermatological Symposium Tackles the Effects of Pollution on Skin17.5.2018 16:03Pressmeddelande

Researchers Present Compelling Evidence Showing the Effects of Pollution on Skin Health at Symposium Sponsored by Mary Kay Inc. DALLAS, May 17, 2018 (GLOBE NEWSWIRE) -- Mary Kay Inc. announced four keynote speakers for its symposium to be held during the prestigious International Investigative Dermatology (IID) Meeting on May 16 to 19, 2018 in Orlando, Florida. The IID meeting occurs once every 5 years, and brings together scientists from across the globe, highlighting the latest in cutting edge science in dermatology. The Mary Kay sponsored Symposium features four global experts including Dr. Liang Liu, Assistant Professor of Dermatology, Columbia University; Dr. Max Costa, Professor and Chairman of the department of Environmental Medicine, New York University School of Medicine; Dr. Jean Krutmann, Chair of Environmental Medicine at the Medical Faculty of Heinrich Heine University Düsseldorf and Director of the Leibniz Research Institute of Environmental Medicine in Dusseldorf, German

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum